Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening

Published on Apr 7, 2020in Cancer Medicine3.491
· DOI :10.1002/CAM4.2973
Carol Cremin4
Estimated H-index: 4
(Provincial Health Services Authority),
Michael K.C. Lee4
Estimated H-index: 4
(Provincial Health Services Authority)
+ 19 AuthorsKasmintan A. Schrader25
Estimated H-index: 25
Sources
Abstract
BACKGROUND: Recent guidelines recommend consideration of germline testing for all newly diagnosed pancreatic ductal adenocarcinoma (PDAC). The primary aim of this study was to determine the burden of hereditary cancer susceptibility in PDAC. A secondary aim was to compare genetic testing uptake rates across different modes of genetic counselling. PATIENTS AND METHODS: All patients diagnosed with PDAC in the province of British Columbia, Canada referred to a population-based hereditary cancer program were eligible for multi-gene panel testing, irrespective of cancer family history. Any healthcare provider or patients themselves could refer. RESULTS: A total of 305 patients with PDAC were referred between July 2016 and January 2019. Two hundred thirty-five patients attended a consultation and 177 completed index germline genetic testing. 25/177 (14.1%) of unrelated patients had a pathogenic variant (PV); 19/25 PV were in known PDAC susceptibility genes with cancer screening or risk-reduction implications. PDAC was significantly associated with PV in ATM (OR, 7.73; 95% CI, 3.10 to 19.33, P = 6.14E-05) when comparing age and gender and ethnicity-matched controls tested on the same platform. The overall uptake rate for index testing was 59.2% and was significantly higher with 1-on-1 consultations and group consultations compared to telehealth consultations (88.9% vs 82.9% vs 61.8%, P < .001). CONCLUSION: In a prospective clinic-based cohort of patients with PDAC referred for testing irrespective of family history, germline PV were detected in 14.1%. PV in ATM accounted for half of all PVs and were significantly associated with PDAC. These findings support recent guidelines and will guide future service planning in this population.
📖 Papers frequently viewed together
20195.74Cancer
4 Citations
4 Citations
References32
Newest
#1Mary B. Daly (Fox Chase Cancer Center)H-Index: 88
#2Robert Pilarski (OSU: Ohio State University)H-Index: 39
Last. Susan Darlow (National Comprehensive Cancer Network)H-Index: 22
view all 33 authors...
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic testing and counseling for hereditary cancer syndromes, and risk management recommendations for patients who are diagnosed with syndromes associated with an increased risk of these cancers. The NCCN panel meets at least annually to review comments, examine relevant new data, and reevaluate and update recommendations. These NCCN Guidelines Insights summarize the panel...
149 CitationsSource
#1Matthew Richardson (UBC: University of British Columbia)H-Index: 2
#2Hae Jung MinH-Index: 1
Last. Kasmintan A. SchraderH-Index: 25
view all 14 authors...
New streamlined models for genetic counseling and genetic testing have recently been developed in response to increasing demand for cancer genetic services. To improve access and decrease wait times, we implemented an oncology clinic-based genetic testing model for breast and ovarian cancer patients in a publicly funded population-based health care setting in British Columbia, Canada. This observational study evaluated the oncology clinic-based model as compared to a traditional one-on-one appro...
6 CitationsSource
#1Michael Goggins (Johns Hopkins University)H-Index: 118
#2Kasper A. Overbeek (Erasmus University Medical Center)H-Index: 3
Last. Marco J. Bruno (Erasmus University Medical Center)H-Index: 23
view all 26 authors...
Background and aim The International Cancer of the Pancreas Screening Consortium met in 2018 to update its consensus recommendations for the management of individuals with increased risk of pancreatic cancer based on family history or germline mutation status (high-risk individuals). Methods A modified Delphi approach was employed to reach consensus among a multidisciplinary group of experts who voted on consensus statements. Consensus was considered reached if ≥75% agreed or disagreed. Results ...
110 CitationsSource
Recent advancements in next-generation sequencing have greatly expanded the use of multi-gene panel testing for hereditary cancer risk. Although genetic testing helps guide clinical diagnosis and management, testing recommendations are based on personal and family history of cancer and ethnicity, and many carriers are being missed. Herein, we report the results from 23,179 individuals who were referred for 30-gene next-generation sequencing panel testing for hereditary cancer risk, independent o...
39 CitationsSource
#1Talia Golan (TAU: Tel Aviv University)H-Index: 14
#2Pascal HammelH-Index: 86
Last. Hedy L. Kindler (U of C: University of Chicago)H-Index: 78
view all 19 authors...
Abstract Background Patients with a germline BRCA1 or BRCA2 mutation make up a small subgroup of those with metastatic pancreatic cancer. The poly(adenosine diphosphate–ribose) polymerase (PARP) in...
613 CitationsSource
#1Heather Symecko (UPenn: University of Pennsylvania)H-Index: 4
#2Rebecca Mueller (UPenn: University of Pennsylvania)H-Index: 10
Last. Susan M. Domchek (HUP: Hospital of the University of Pennsylvania)H-Index: 90
view all 8 authors...
1506Background: Germline genetic testing (GT) for cancer susceptibility is recommended for pancreatic and advanced prostate cancer patients, due to potential implications for targeted therapies and...
5 CitationsSource
: We report a case of early-onset pancreatic ductal adenocarcinoma in a patient harboring biallelic MUTYH germline mutations, whose tumor featured somatic mutational signatures consistent with defective MUTYH-mediated base excision repair and the associated driver KRAS transversion mutation p.Gly12Cys. Analysis of an additional 730 advanced cancer cases (N = 731) was undertaken to determine whether the mutational signatures were also present in tumors from germline MUTYH heterozygote carriers or...
14 CitationsSource
#1Evan J. Walker (UCSF: University of California, San Francisco)H-Index: 9
#2Julia Carnevale (UCSF: University of California, San Francisco)H-Index: 11
Last. Andrew H. Ko (UCSF: University of California, San Francisco)H-Index: 45
view all 8 authors...
Hereditary predisposition is estimated to account for 10% of all pancreatic cancer cases. However, referral patterns and clinical workflow for germline testing in this disease differ significantly by institution, and many at-risk patients may not undergo appropriate counseling and testing. We undertook an analysis of patients diagnosed with pancreatic cancer (PDAC) who were referred to the Clinical Genetics program of a high-volume academic center over a 3-year period to assess referral frequenc...
6 CitationsSource
#1Elena M. Stoffel (UM: University of Michigan)H-Index: 37
#2Shannon E. McKernin (American Society of Clinical Oncology)H-Index: 7
Last. Alok A. Khorana (Case Western Reserve University)H-Index: 67
view all 11 authors...
PurposeAn ASCO provisional clinical opinion (PCO) offers timely clinical direction to ASCO’s membership and other health care providers. This PCO addresses identification and management of patients and family members with possible predisposition to pancreatic adenocarcinoma.MethodsASCO convened an Expert Panel and conducted a systematic review of the literature published from January 1998 to June 2018. Results of the databases searched were supplemented with hand searching of the bibliographies ...
49 CitationsSource
#1Matthew B. Yurgelun (Harvard University)H-Index: 23
#2Anu Chittenden (Harvard University)H-Index: 10
Last. Brian M. Wolpin (Harvard University)H-Index: 64
view all 38 authors...
Germline variants in double-strand DNA damage repair (dsDDR) genes (e.g., BRCA1/2) predispose to pancreatic adenocarcinoma (PDAC) and may predict sensitivity to platinum-based chemotherapy and poly(ADP) ribose polymerase (PARP) inhibitors. We sought to determine the prevalence and significance of germline cancer susceptibility gene variants in PDAC with paired somatic and survival analyses. Using a customized next-generation sequencing panel, germline/somatic DNA was analyzed from 289 patients w...
81 CitationsSource
Cited By10
Newest
#1Yifan Wang (MUHC: McGill University Health Centre)H-Index: 5
#2Bryn Golesworthy (MUHC: McGill University Health Centre)
Last. Zu-Hua Gao (MUHC: McGill University Health Centre)H-Index: 26
view all 13 authors...
BACKGROUND Traditional medical genetics models are unable to meet the growing demand for germline genetic testing (GT) in patients with exocrine pancreatic cancer (PC). This study investigates the impact of an ambulatory oncology clinic-based GT model. METHODS From 2012 to 2021, patients with PC were prospectively enrolled and considered for GT. Two chronological cohorts were compared: (1) the preuniversal genetic testing (pre-UGT) cohort, which received GT based on clinical criteria or family h...
Source
#1Greet Wieme (Ghent University Hospital)H-Index: 5
#2Jan Kral (First Faculty of Medicine, Charles University in Prague)H-Index: 1
Last. Jana Soukupova (First Faculty of Medicine, Charles University in Prague)H-Index: 8
view all 25 authors...
(1) Background: The proportion and spectrum of germline pathogenic variants (PV) associated with an increased risk for pancreatic ductal adenocarcinoma (PDAC) varies among populations. (2) Methods: We analyzed 72 Belgian and 226 Czech PDAC patients by multigene panel testing. The prevalence of pathogenic variants (PV) in relation to personal/family cancer history were evaluated. PDAC risks were calculated using both gnomAD-NFE and population-matched controls. (3) Results: In 35/298 (11.7%) patie...
Source
#2Tanya Dwarte (Garvan Institute of Medical Research)H-Index: 1
Last. Amber L. Johns (Garvan Institute of Medical Research)H-Index: 27
view all 0 authors...
Background null The Australian Pancreatic Cancer Screening Program (APCSP) offers endoscopic ultrasound surveillance for individuals at increased risk of pancreatic ductal adenocarcinoma (PDAC) with all participants requiring assessment by a Familial Cancer Service before or after study enrolment. null Methods null Individuals aged 40-80 years (or 10 years younger than the earliest PDAC diagnosis) were eligible for APCSP study entry if they had 1) ≥ two blood relatives with PDAC (at least one of...
1 CitationsSource
#1Noelle R. Danylchuk (University of Arkansas for Medical Sciences)H-Index: 4
#2Lola Cook (IU: Indiana University)H-Index: 4
Last. Jennifer MalinowskiH-Index: 10
view all 8 authors...
Telehealth options, such as telephone counseling or videoconferencing, for service delivery in genetic counseling are becoming more widely accepted. However, until now, there has not been a systematic review of the literature focused specifically on genetic counseling outcomes for telehealth. We performed a systematic evidence review to compare telehealth genetic counseling (THGC), including videoconferencing and telephone counseling, across specialties to in-person genetic counseling (IPGC) for...
Source
#1Esteban Astiazaran-Symonds (NIH: National Institutes of Health)H-Index: 1
#2Alisa M. Goldstein (NIH: National Institutes of Health)H-Index: 86
The genetics of pancreatic ductal adenocarcinoma (PDAC) is complex with patients reported to harbor germline pathogenic variants (PVs) in many different genes. PDAC patients with familial pancreatic cancer (FPC) are more likely to carry germline PVs but there is no consensus main gene involved in FPC. We performed a systematic review of publications from PubMed and Scopus reporting PVs in patients with FPC, sporadic pancreatic cancer (SPC) and unselected cohorts of PDAC patients undergoing genet...
Source
Although CDKN2A is well-known as a susceptibility gene for melanoma and pancreatic cancer, germline variants have also been anecdotally associated with a broader range of neoplasms including neural system tumors, head and neck squamous cell carcinomas, breast carcinomas, as well as sarcomas. The CDKN2A gene encodes for two distinct tumor suppressor proteins, p16INK4A and p14ARF, however, the independent association of germline alterations affecting these two proteins with cancer is under-appreci...
2 CitationsSource
#1Binbin Zheng-Lin (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 3
#2Eileen M. O'Reilly (Cornell University)H-Index: 73
Abstract The paradigm for treatment of PDAC is shifting from a “one size fits all” of cytotoxic therapy to a precision medicine approach based on specific predictive biomarkers for a subset of patients. As the genomic landscape of pancreatic carcinogenesis has become increasingly defined, several oncogenic alterations have emerged as actionable targets and their use has been validated in novel approaches such as targeting mutated germline DNA damage response genes (BRCA) and mismatch deficiency ...
2 CitationsSource
#1Elena FountzilasH-Index: 14
Last. Grigorios Rallis (A.U.Th.: Aristotle University of Thessaloniki)H-Index: 5
view all 35 authors...
Our aim was to determine the prevalence, prognostic and predictive role of germline pathogenic/likely pathogenic variants (P/LPVs) in cancer predisposing genes in patients with pancreatic ductal adenocarcinoma (PDAC). Germline testing of 62 cancer susceptibility genes was performed on unselected patients diagnosed from 02/2003 to 01/2020 with PDAC, treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated Centers. The main endpoints were prevalence of P/LPVs and overall survival (OS). P/...
2 CitationsSource
#2Nidhi Sharma (University of Texas at Austin)H-Index: 3
Last. Holly J. Pederson (Cleveland Clinic)H-Index: 6
view all 3 authors...
Source
#1Manuel Gentiluomo (UniPi: University of Pisa)H-Index: 6
#2Federico Canzian (DKFZ: German Cancer Research Center)H-Index: 82
Last. Daniele Campa (UniPi: University of Pisa)H-Index: 34
view all 6 authors...
Pancreatic cancer (PC), particularly its most common form, pancreatic ductal adenocarcinoma (PDAC), is relatively rare but highly lethal. Knowledge about PC risk factors could in the long term contribute to early diagnosis and mortality reduction. We review the current status of research on germline genetic factors for PC risk. Genome-wide association studies (GWAS) successfully identified common loci convincingly associated with PC risk, an endeavor that is still ongoing. The function of only a...
5 CitationsSource